prostaglandin J 2 , and troglitazone significantly decreased LPS-induced tumor necrosis factor-␣ production by AMs. These ligands markedly upregulated the expression of CD36, a scavenger receptor that mediates the phagocytosis of apoptotic neutrophils. Indeed, ligand-treated AMs ingested a significantly higher number of apoptotic neutrophils than untreated AMs. These data indicate that PPAR␥ expressed by AMs play an antiinflammatory role through inhibiting cytokine production and increasing their CD36 expression together with the enhanced phagocytosis of apoptotic neutrophils, which is an essential process for the resolution of inflammation. This suggests the potential therapeutic application of PPAR␥ ligands in inflammatory disorders of the lung.
to phagocytose infiltrating cells into the lung (3, 4) . Collectively, AMs regulate lung inflammation in different ways depending on the phase of the lung inflammation, thus tightly elaborating the processes of this inflammation. Based on these observations, AMs could be one of the major therapeutic targets for inflammatory disorders of the lung. Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily that heterodimerize with the retinoid X receptor (5, 6) . The three known PPAR subtypes, ␣, ␥, and ␦ (␤), which are associated with selective ligands, show distinct tissue distributions (7, 8) . PPAR␥ is predominantly expressed in adipose tissue, and its target genes encode enzymes involved in fatty acid synthesis (9) . It is thus thought that PPAR␥ plays an important role in glucose metabolism and adipogenesis. PPAR␥ is activated by diverse synthetic and naturally occurring ligands, including antidiabetic thiazolidinediones (10, 11) , polyunsaturated fatty acids (12, 13), 15-deoxy-⌬ 12,14 prostaglandin J 2 (15d-PGJ 2 ) (14, 15) , and components of oxidized low-density lipoproteins (16) . Unexpectedly, recent studies have indicated the expression of PPAR␥ in monocytes (Mo) and macrophages (17) (18) (19) (20) . Low levels of PPAR␥ were detected in murine bone marrow macrophages, whereas activated peritoneal macrophages showed much higher levels of its expression (18) . Although the function of PPAR␥ in Mo and macrophages is not fully determined, several reports have suggested an antiinflammatory activity of PPAR␥ in these cells. Indeed, PPAR␥ ligands inhibited inducible nitric oxide synthase expression in murine peritoneal macrophages (18) as well as the production of the inflammatory cytokines, such as tumor necrosis factor ␣ (TNF-␣), interleukin-1␤, and interleukin-6, from human Mo (19) . It is suggested that these inhibitory effects of PPAR␥ are mediated by negatively regulating the expression of proinflammatory genes and antagonizing the activities of transcription factors (18, 21, 22) . Taken together, these cumulative data provide a new insight into the function of PPAR␥ as an antiinflammatory mediator in Mo and macrophages. However, the expression of PPAR␥ and its functional role in AMs are currently unknown. Interestingly, recent data demonstrated that CD36, a scavenger receptor, is upregulated by PPAR␥ on Mo and macrophages (16, 23) . PPAR␥ modulates CD36 gene expression through direct interaction with the proximal promoter via a specific response element. The primary function of CD36 has been shown to be associated with clearance of apoptotic cells arising during development, normal homeostasis, and inflammation (24, 25) . At the inflammatory sites, CD36 functions as a receptor for apoptotic neutrophils, which mediates their phagocytosis by macrophages (24, 26, 27) . During early inflammatory processes, neutrophils are recruited from the circulation in response to a series of coordinated signals (28) . In the resolving phase, the accumulated neutrophils undergo apoptosis and are subsequently phagocytosed by macrophages (29) . This removal of apoptotic neutrophils by macrophage phagocytosis is a critical process for the resolution of inflammation. In the lung, it is thus hypothesized that the activation of PPAR␥ enhances CD36 expression by AMs, which in turn augments their phagocytic capacity for apoptotic neutrophils. However, few data are avail-able about CD36 expression by AMs (30) . The aim of the present study was to investigate the expression of PPAR␥ by AMs. To address this, we first determined the expression of PPAR␥ in human AMs by reverse transcription polymerase chain reaction and Western blotting. Next, we examined the effect of the PPAR␥ ligand on the production of TNF-␣ and CD36 expression by the AMs. Finally, we clarified whether the ligand dependent stimulation of PPAR␥ in the AMs augments their capacity to phagocytose apoptotic neutrophils. Some of the results of this study have been previously reported in the form of abstracts (31, 32) .
METHODS

Preparation of Human Alveolar Macrophages
Bronchoalveolar lavage was performed on normal healthy donors and AMs were purified as previously described (33) (see online supplement for details). This study was approved by the ethics committee of Hamamatsu University School of Medicine, and informed consent was obtained.
Preparation of Human Peripheral Blood Monocytes
Peripheral blood mononuclear cells were isolated from heparinized whole blood of normal, healthy donors by density gradient centrifugation with Lymphoprep (Nycomed, Oslo, Norway). CD14 ϩ cells were separated by magnetic sorting with a MACS (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's instructions (see online supplement for details).
Neutrophil Isolation and Induction of Apoptosis
Neutrophils were isolated from heparinized whole blood of normal, healthy donors by a combination of dextran sedimentation and centrifugation with Polymorphprep (Nycomed). The purity of neutrophils was greater than 98%, as determined by their morphology. The neutrophils were aged by culturing to undergo apoptosis (28) (see online supplement for details).
RNA Isolation and Complimentary DNA Synthesis
Total RNA was isolated from AMs and Mo by the acid guanidinium thiocyanate-phenol-chloroform extraction method (34) (see online supplement for details).
Polymerase Chain Reaction
We designed the primers for PPAR␥ and ␤-actin to span an intron of each genome. For the other receptors, we used the primers described in previous a previous report (35) . The primer sequences were as follows: PPAR␣: 5Ј-TCATCAAGAAGACGGAGTCG-3Ј and 5Ј-CGGTTAC-CTACAGCTCAGAC-3Ј, amplifying a 213-bp product; PPAR␦: 5Ј-TCCCTCTTTCTCAGTTCCTC-3Ј and 5Ј-CAGGAGACAGAAGT-GAGGAC-3Ј, amplifying a 289-bp product; PPAR␥: 5Ј-CAGCATTT-CTACTCCACATT-3Ј and 5Ј-ATCTCCACAGACACGACATT-3Ј, amplifying a 222-bp product; and ␤-actin: 5Ј-GGGCATGGGTCA-GAAGGATT-3Ј and 5Ј-GAGGCGTACAGGGATAGCAC-3Ј, amplifying a 302-bp product. Polymerase chain reaction amplification was performed in the DNA Thermal Cycler (Perkin-Elmer Cetus, Norwalk, CT) and the expressions of this messenger RNA (mRNA) were evaluated by densitometry (see online supplement for details).
Preparation of Cell Extracts and Western Blot Analysis
For Western blotting, a positive control was generated by transiently transfecting a PPAR␥ expression plasmid (7) into CV-1 cells using a calcium-phosphate precipitation method. Protein extracts of AMs, Mo, and trasfected CV-1 cells were prepared and the expression of PPAR␥ protein was assessed by Western blotting (see online supplement for details).
Measurement of TNF-␣ Production
AMs were seeded at a density of 1.5 ϫ 10 5 cells/well in RPMI 1640 with 5% fetal calf serum into 24-well tissue culture plates. The cells were treated with 15d-PGJ 2 (Cayman, Ann Arbor, MI) or troglitazone, kindly provided by Sankyo (Tokyo, Japan), for 1 hour before the addition of 0.1 ng/ml LPS (Sigma, St. Louis, MO). After 24 hours incubation at 37ЊC in 5% CO 2 , the supernatants were harvested. The concentrations of TNF-␣ were measured by enzyme-linked immunosorbent assay kit (R&D Systems, Minneapolis, MN).
Measurement of CD36 Expression by Flow Cytometric Analysis
AMs were seeded at a density of 1 ϫ 10 6 cells/ml in RPMI 1640 with 10% fetal calf serum into 12-well tissue culture plates. After a 6-dayincubation with 15d-PGJ 2 or troglitazone, the cells were harvested. They were incubated with fluorescein isothiocyanate-conjugated anti-CD36 (clone FA6.152, mouse IgG1; Immunotech, Marseille, France) monoclonal antibodies for 30 minutes on ice. After washing in PBS, the cells were analyzed with EPICS Profile-II (Beckman Coulter, Fullerton, CA). The expression of CD36 was evaluated as the percentage positive cells and the mean fluorescence intensity (MFI).
Phagocytosis Assay
Phagocytosis of apoptotic neutrophils by AMs was assessed using previously described methods (24, 36, 37 ) (see online supplement for details). AMs cultured in the presence of 15d-PGJ 2 for 6 days were pretreated with or without 50 g/mL of anti-CD36 monoclonal antibody (Immunotech) for 30 minutes.
Statistical Analysis
Unpaired t test or one-way analysis of variance was used for comparisons of groups. p Values of less than 0.05 were considered significant. All data are expressed as mean Ϯ SEM.
RESULTS
Expression of PPAR␥ mRNA and Protein in Human Ams
Using reverse transcription polymerase chain reaction, mRNA of each PPAR subtype (PPAR␣, PPAR␥, and PPAR␦) was detected in freshly isolated human AMs ( Figure 1A) . Compared with peripheral blood Mo, the relative intensity of PPAR␥ mRNA was 10-fold higher in AMs (p Ͻ 0.01), whereas no significant difference was found in the expression of PPAR␣ or PPAR␦ between them ( Figure 1B ). Western blot analysis showed strong expression of PPAR␥ protein in AMs, whereas a weak signal was detected in Mo ( Figure 1C ).
PPAR␥ Ligands Inhibit LPS-induced TNF-␣ Production by Ams
To define the functional role of PPAR␥ in AMs, we first examined the effect of 15d-PGJ 2 , a natural ligand of PPAR␥, and troglitazone, antidiabetic thiazolidinedione, on cytokine production by AMs. We measured the TNF-␣ concentrations in culture supernatants of LPS-stimulated AMs after treatment with graded doses of 15d-PGJ 2 or troglitazone. LPS (0.1 ng/ml) elicited considerable amounts of TNF-␣ production by AMs. When adding these ligands to the cultures, the LPS-induced TNF-␣ production by AMs was significantly inhibited in a dose-dependent manner (Figure 2) , indicating that the PPAR␥ activation reduced the production of TNF-␣ by AMs. In contrast, the same ligands failed to decrease LPS-induced TNF-␣ production by blood Mo (data not shown).
PPAR␥ Ligands Upregulate CD36 Expression by Ams
We tested the effect of 15d-PGJ 2 and troglitazone on the expression of CD36, which mediates phagocytosis of apoptotic neutrophils by AMs. Although freshly isolated AMs did not express CD36, the treatment with 15d-PGJ 2 or troglitazone readily induced CD36 expression, which increased in a time-dependent manner ( Figure 3A) . Six days after the treatment, more than 50% of cultured AMs became positive for CD36, while the control cultures failed to induce its expression ( Figure 3B) . In blood Mo, 15d-PGJ 2 or troglitazone did not significantly increase CD 36 expression (data not shown). 
15d-PGJ 2 Enhanced Capacity of AMs to Phagocytose Apoptotic Neutrophils
To determine whether ligand activation of PPAR␥ augments phagocytic capacity of AMs, we performed an in vitro phagocytosis assay using apoptotic neutrophils. After culturing for 6 days in the presence of 15d-PGJ 2 , AMs that had been induced to express CD36 were used for the phagocytosis assay. As shown in Figure 4A , we easily detected ingested neutrophils in AMs and assessed their phagocytic capacity by counting the numbers of ingested neutrophils. 15d-PGJ 2 -treated AMs ingested a significantly higher number of apoptotic neutrophils than did untreated AMs (p Ͻ 0.01) ( Figure 4B ). Treatment of anti-CD36 antibody inhibited phagocytosis of 15d-PGJ 2 -treated AMs (p Ͻ 0.01) (Figure 4B ), suggesting that enhanced phagocytic capacity of these AMs by 15d-PGJ 2 is largely associated with the increase in their CD36 expression. Because phagocytosis of apoptotic neutrophils at inflammatory sites is a critical determinant for resolving inflammation, AMs stimulated by ligand for PPAR␥ may be actively involved in this process of the lung.
DISCUSSION
In the present study, we examined the expression of PPAR␥ by human AMs and its functional role in lung inflammation. We demonstrated for the first time that freshly isolated human AMs strongly expressed PPAR␥ mRNA and protein. Further, ligands of PPAR␥ reduced the LPS-induced TNF-␣ production and enhanced the CD36 expression by AMs together with an increase in their capacity to phagocytose apoptotic neutrophils. These data suggest that PPAR␥ in AMs has an antiinflammatory role.
Evidence has been accumulated indicating that PPAR␥ plays a role in regulating inflammation. In Mo, PPAR␥ ligands suppress the expression of TNF-␣, interleukin-6, and interleukin-1␤ (19) , whereas in macrophages they inhibit the expression of inducible nitric oxide synthase, matrix metalloprotease-9, and scavenger receptor-A (18) . Several studies have demonstrated that an administration of PPAR␥ ligands in vivo inhibited adjuvant-induced arthritis (38) , colitis (39) , and atherosclerosis (40) in animal models. These findings have raised the possibility that ligands for PPAR␥ might be useful for the treatment of inflammatory disorders. However, PPAR␥ expression and its function in resident tissue macrophages, particularly human AMs, still remain unclear. In the present study, we first determined PPAR␥ expression by human AMs. Using reverse transcription polymerase chain reaction and Western blotting, we demonstrated the expression of PPARs mRNA and protein in freshly isolated AMs. mRNA expression of PPAR␥, but not of PPAR␣ or ␦, by AMs was much higher than that by peripheral blood Mo. Moreover, the expression of PPAR␥ protein was much stronger in AMs than Mo. Although the mechanisms of the strong expression of PPAR␥ in AMs are not clear, several studies have shown that this expression increased during the differentiation in monocyte/macrophage lineage cells (20) . For example, PPAR␥ expression was shown to be upregulated during the differentiation of bone marrow progenitor cells in response to macrophage colony-stimulating factor and granulocyte/macrophage colony stimulating factor (41) . Because AMs are highly differentiated macrophages that are specifically adapted to the particular environment of the lung, this may be attributable to their enhanced expression of PPAR␥.
To elucidate the functional role of PPAR␥ in human AMs, we next examined the effect of its ligand on cytokine production by AMs. We found that 15d-PGJ 2 and troglitazone, the specific ligands of PPAR␥, markedly decreased the LPS-induced TNF-␣ production by AMs in a dose-dependent manner. Although the precise mechanisms by which PPAR␥ ligands exert antiinflammatory effects are poorly understood, recent studies have revealed that PPAR␥ inhibits the expression of inflammatory genes by the interference with nuclear factor B (NF-B), activator protein-1, and signal transducers and activators of transcription-1 (18, 22, 42, 43) . For example, PPAR␥ was shown to suppress NF-B-mediated activation in interleukin-12 p40 promoter through both inhibition of the NF-B-DNA binding and physical interactions between NF-B and PPAR␥ (21) . Because TNF-␣ promoter activity occurs by stimulation of the NF-B signaling pathway (44) , the inhibition of TNF-␣ production by the ligands of PPAR␥ is likely due to antagonizing NF-B activity in AMs. However, further studies will be required to clarify the precise molecular mechanisms of PPAR␥-mediated inhibition of cytokine production by AMs. A variety of inhaled microbes and particles can potentially induce inflammation in the lung, resulting in tissue damage. To limit this inflammation, AMs have been proposed to play an important role in maintaining immunologic homeostasis in the lung via their immunosuppressive activity (45, 46) . In this context, it seems to be rational that AMs express high levels of functional PPAR␥ protein.
Finally, we determined whether PPAR␥ activation increased CD36 expression by human AMs, and consequently augmented their phagocytic capacity for apoptotic neutrophils. Although freshly isolated AMs did not express CD36, treatment with the PPAR␥ ligands readily induced its expression, which increased in a time-dependent manner. The human CD36 gene contains a PPAR␥-responsive element, which was shown to be functional in Mo/macrophages (23, 47) . Thus, the PPAR␥ ligand likely activated the transcription of the CD36 gene in AMs. Recently, it has been reported that CD36 also functions as a receptor for apoptotic neutrophils as well as Plasmodium falciparum-parasitized erythrocytes (48, 49) , thereby mediating their phagocytosis. Indeed, CD36 was shown to be required for phagocytosis of apoptotic neutrophils by human blood monocyte-derived macrophages that cooperate with either a phosphatidylserine, vitronectin receptor (␣ v ␤ 3 ), or thrombospondin (24, 26, 27) . In inflammation, removal of infiltrating cells that undergo apoptosis is thought to be an essential process for its resolution (4, 29) . Of the cells involved in this process, macrophages are the most prominent. In the present study, we found that human AMs that had been induced to express CD36 after treatment with 15d-PGJ 2 showed enhanced phagocytosis of apoptotic neutrophils. The enhancement of phagocytic capacity is likely to be mediated by increased CD36 expression because anti-CD36 antibody abrogated this enhancement. Collectively, our data suggest that PPAR␥ activation in AMs promotes the resolution of lung inflammation by their enhanced phagocytic capacity for apoptotic neutrophils.
15d-PGJ 2 is a naturally occurring prostaglandin D 2 metabolite that has been identified as a ligand for PPAR␥ (14, 15) . Interestingly, a recent study by Gilroy and colleagues demonstrated an increased local production of 15d-PGJ 2 in acute lung inflammation (50) . They measured the exudate levels of prostaglandins, such as PGE 2 , PGD 2 (precursor of prostaglandin J series), and 15d-PGJ 2 , and showed that PGD 2 and 15d-PGJ 2 increased at both initial and, to a greater extent, late phases of lung inflammation, while PGE 2 was produced only at the initial phase. These data suggested that the profiles of prostaglandins produced in the inflammation may change from PGE 2 -dominant profile to PGD 2 -and 15d-PGJ 2 -dominant profile during the resolution of inflammation. Based on our findings, locally generated 15d-PGJ 2 during the late phase of lung inflammation could activate PPAR␥ in AMs, which in turn reduces their cytokine production and increase their CD36 expression together with an enhancement of their phagocytic capacity.
In summary, we demonstrated that human AMs strongly expressed PPAR␥, of which activation led to the inhibition of LPS-induced TNF-␣ production and the induction of CD36 expression by the AMs, thereby enhancing their phagocytosis of apoptotic neutrophils. These data indicate an antiinflammatory role for PPAR␥ expressed by AMs in the lung, suggesting a potential therapeutic application of its ligand in inflammatory disorders of the lung.
